Eric Gyuricsko
Pediatric Endocrinology · Norfolk, VANPI 1215987854
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Pfizer accounts for 76.8% of it on its own, with 22 other manufacturers making up the rest. 2025 is the largest year on record at $4,114, more than ten times the $206 reported in 2019. Among pediatric endocrinology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 64 payments — averaging $119.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$6K
- Arbor Pharmaceuticals, Inc.$206
- Medtronic$186
- Biomarin Pharmaceutical Inc.$180
- Novo Nordisk$170
- Ascendis Pharma Endocrinology Inc$165
- plus $865 from 17 others
Across 21 payments — averaging $2175.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ascendis Pharma Endocrinology Inc$20K
- Ultragenyx Pharmaceutical Inc.$19K
- Pfizer$7K
What the payments were for
- Speaking & faculty fees$3,60047%
- Travel & lodging$1,85724%
- Food & beverage$2,16528%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 13 | $5,876 |
| Arbor Pharmaceuticals, Inc. | 4 | $206 |
| Medtronic | 2 | $186 |
| Biomarin Pharmaceutical Inc. | 3 | $180 |
| Novo Nordisk | 3 | $170 |
| Ascendis Pharma Endocrinology Inc | 4 | $165 |
| Xeris Pharmaceuticals, Inc. | 2 | $132 |
| Kyowa Kirin, Inc. | 6 | $123 |
| AbbVie | 5 | $100 |
| Neurelis, Inc. | 1 | $93 |
| Sandoz | 2 | $57 |
| Azurity Pharmaceuticals, Inc. | 3 | $53 |
| Dexcom, Inc. | 2 | $53 |
| Neurocrine Biosciences, Inc. | 2 | $39 |
| BETA Bionics, Inc. | 2 | $35 |
| Insulet Corporation | 2 | $34 |
| Abbott | 2 | $34 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Endo Pharmaceuticals Inc. | 1 | $22 |
| Soleno Therapeutics, Inc. | 1 | $19 |
| Sequel Med Tech, LLC | 1 | $18 |
| Endo USA, Inc. | 1 | $16 |
| Amphastar Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NGENLA$3,600
- GENOTROPIN$2,059
- MINIMED 780G$172
- VOXZOGO$124
- Sogroya$120
- GVOKE PFS$115
How this compares
$7,647 in reported general payments places this provider in the 90th percentile of 36 pediatric endocrinology providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metformin Hcl | 23 | $244 |
Paid to pharmacies, not to this prescriber.
Other pediatric endocrinology in Norfolk
- Kent ReifschneiderNorfolk$133K
- Melinda PennNorfolk$2K
- Nicole NejedlyNorfolk$782
- Natinder SainiNorfolk$746
- Marta Satin-SmithNorfolk$661
- Melissa RussellNorfolk$634
- Melissa BurykNorfolk$172
- Bryce NelsonRichmond$115K
- David RepaskeCharlottesville$51K
- Melissa SchoelwerCharlottesville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.